ShareValue scores for CRMD: Valuation 77, Quality 78, Growth 68, Health 49.

CorMedix Inc logo

CRMD
NASDAQ

CorMedix Inc

$5.23(-7.60%)

Updated

Loading chart...
Sentiment

Pulse

Rating

Moderate

Trap Risk

P/E to median

Not enough data
Valuation
77
Undervalued

vs US-listed small-cap Healthcare stocks

Price vs Value
Quality
78
Strong
Business Strength
Growth
68
Moderate
Revenue & Earnings
Health
49
Moderate
Financial Stability
Price trend
65
Strong
Separate from the four scores

Company Details

About

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New Jersey.

Score Analysis

AI Investment Thesis

Data as of:Nov 6, 2026

By using ShareValue.ai you agree to our Terms and Privacy Policy. Educational platform, not investment advice.